|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
A genome-wide association study identifies a breast cancer risk variant in ERBB4 at 2q34: results from the Seoul Breast Cancer Study.
|
22452962 |
2012 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A number of single nucleotide polymorphisms (SNPs) in ERBB4 gene have been linked to increase the risk of breast cancer.
|
28508829 |
2018 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
SNP rs13393577 at chromosome 2q34, located in the Epidermal Growth Factor Receptor 4 (ERBB4) gene, showed a consistent association with breast cancer risk with combined odds ratios (95% CI) of 1.53 (1.37-1.70) (combined P for trend = 8.8 × 10-14).
|
22452962 |
2012 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In analysis of selected candidate cancer susceptibility genes, two MSR1 SNPs (rs9325782, GEE p = 0.008 and rs2410373, FBAT p = 0.021) were associated with prostate cancer and three ERBB4 SNPs (rs905883 GEE p = 0.0002, rs7564590 GEE p = 0.003, rs7558615 GEE p = 0.0078) were associated with breast cancer.
|
17903305 |
2007 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
ErbB4 receptor polymorphism 2368A>C and risk of breast cancer.
|
30336339 |
2018 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The present study aimed to predict potential 3'‑UTR variants of ErbB4 that alter the target binding site of microRNAs (miRNAs) and to clarify the association of the potential variant with the risk of developing breast cancer.
|
27035115 |
2016 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These data present the germ-line ERBB4 variant -815A>T as a novel prognostic marker in high-risk early breast cancer and indicate the presence of rare but potentially oncogenic somatic ERBB4 mutations in breast cancer.
|
25036186 |
2014 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We detected the ERBB4 somatic mutations in 3 of 180 gastric carcinomas (1.7%), 3 of 104 colorectal carcinomas (2.9%), 5 of 217 nonsmall cell lung cancers (2.3%) and 1 of 94 breast carcinomas (1.1%).
|
16187281 |
2006 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Failure to account for isoform-specific functions in previous studies may account for conflicting reports on the role of ERBB4 in breast cancer.
|
25516216 |
2014 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Heregulins are a family of ligands for the ErbB3/ErbB4 receptors that play important roles in breast cancer cell proliferation and tumorigenesis.
|
16428439 |
2006 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
HER4 in breast cancer: comparison of antibodies against intra- and extra-cellular domains of HER4.
|
16606438 |
2006 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Overexpression of heregulin, a potent ligand that activates HER3 and HER4 receptors, plays a significant role in the development of chemotherapy resistance in breast cancer patients.
|
28797930 |
2017 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
More recently, the other two members of the ErbB receptor family, ErbB3 and ErbB4, have been implicated in antihormone resistance in breast cancer.
|
21396094 |
2011 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
However, c-erbB-4 antagonizes the c-erbB-2 effect on clinical course in breast carcinomas.
|
11748637 |
2002 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Ecotropic virus, which normally does not infect human cells, when pseudotyped with the modified envelope protein now crosses species to infect human breast cancer cell lines that overexpress HER-2 (human epidermal growth factor receptor; also called ERBB2) and HER-4 (also called ERBB4), while human breast cancer cell lines expressing low levels of these receptors remain resistant to infection.
|
7568210 |
1995 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Finally, knockdown of PIAS3 with siRNA partially rescued the inhibitory effect of the ErbB4 ICD on differentiation of MDA-MB-468 breast cancer and HC11 mammary epithelial cells.
|
22584572 |
2012 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
This review focuses on recent advances in our understanding about the role of ErbB4 in breast carcinogenesis, as well as in the potential clinical relevance of ErbB4 in breast cancer prognostics and therapy.
|
18454307 |
2008 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Some miRNAs (e.g., miR-139-5p and miR-9) and their target gene SFRP1, as well as several other miRNAs (e.g., miR-375, miR-592, and miR-135a) and their target genes (e.g., ESR1 and ERBB4), might be crucial in the pathogenesis of primary breast cancer.
|
25680412 |
2015 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Recent data suggest that HER4 unfavorably affects the endocrine treatment of postmenopausal breast cancer patients with tamoxifen and therefore might represent an additional therapeutic target in luminal breast cancer.
|
31139328 |
2019 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Conflicting reports of the prognostic value of HER4 in breast cancer may be explained by distinct activities of the HER4 intracellular domain, 4ICD.
|
19808643 |
2009 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Due to these correlations, erbB-4 oncogene amplification can be assumed to be of prognostic or predictive value in the diagnosis of breast cancer.
|
9858771 |
1998 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Overexpressing ERBB4 in cultured mammary epithelial cells or adding the ERBB4 ligand neuregulin 1 (NRG1) to breast cancer cell cultures promoted the expression of genes regulated by YAP, such as CTGF.
|
25492965 |
2014 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The HER4 intracellular domain (4ICD) is a potent estrogen receptor (ERalpha) coactivator with activities in breast cancer and the developing mammary gland that appear to overlap with progesterone receptor (PgR).
|
20550710 |
2010 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The precise biological role of this oncogenic signaling pathway (which also involves the HER4 gene) in breast cancer is unclear.
|
9563896 |
1998 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Administration of heregulin-beta2 (HRG), a ligand for erbB3 and erbB4, to growth arrested T-47D human breast cancer cells leads to activation of both the PI3-kinase and MAP kinase signalling pathways and potent stimulation of cell cycle progression.
|
9652748 |
1998 |